SpringerLink
Log in

Glucose-dependent diuresis in relation to improvements in renal-tubular markers of sodium-glucose cotransporter-2 inhibitors in hospitalized heart failure patients with diabetes

  • Original Article
  • Published:
Heart and Vessels Aims and scope Submit manuscript

Abstract

Clinical parameters with correlation to diuretic effects after initiation of sodium-glucose cotransporter-2 (SGLT2) inhibitors are unclear. We aimed to identify the factors associated with the diuretic effect observed following the initiation of SGLT2 inhibitors in patients with diabetes having an acute heart failure (HF). Fifty-six patients included were hospitalized for acute HF with diabetes and started on SGLT2 inhibitors. Changes in urine volume (ΔUV) and blood/urine laboratory parameters before and during the first 4 days of therapy were evaluated. Data were prospectively obtained under clinically stable conditions after initial HF treatment. UV increased following the initiation of SGLT2 inhibitors [UV at baseline (BL): 1383 ± 479 mL/day; ΔUV over 4 days: + 189 ± 358 mL/day]. Multivariate analysis revealed no association between BL-hemoglobin A1c or BL-estimated glomerular filtration rate and ΔUV. Conversely, higher BL-fasting plasma glucose (FPG) and higher BL-urine N-acetyl-β-D-glucosaminidase (NAG) were associated with a higher ΔUV. ΔUV was inversely associated with ΔFPG and ΔNAG, and positively associated with Δurinary sodium excretion. Elevated FPG and NAG both improved over 4 days of treatment. In conclusion, the diuretic effect of SGLT2 inhibitors was glycemia-dependent, and was associated with a reduction in elevated renal-tubular markers in hospitalized HF complicated with diabetes.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Lytvyn Y, Bjornstad P, Udell JA, Lovshin JA, Cherney DZI (2017) Sodium glucose cotransporter-2 inhibition in heart failure: potential mechanisms, clinical applications, and summary of clinical trials. Circulation 136(17):1643–1658

    Article  CAS  Google Scholar 

  2. Kambara T, Shibata R, Osanai H, Nakashima Y, Asano H, Murohara T, Ajioka M (2019) Importance of sodium-glucose cotransporter 2 inhibitor use in diabetic patients with acute heart failure. Ther Adv Cardiovasc Dis 13:1753944719894509

    Article  CAS  Google Scholar 

  3. Damman K, Beusekamp JC, Boorsma EM, Swart HP, Smilde TDJ, Elvan A, van Eck JWM, Heerspink HJL, Voors AA (2020) Randomized, double-blind, placebo-controlled, multicentre pilot study on the effects of empagliflozin on clinical outcomes in patients with acute decompensated heart failure (EMPA-RESPONSE-AHF). Eur J Heart Fail 22(4):713–722

    Article  CAS  Google Scholar 

  4. Wright EM (2001) Renal Na(+)-glucose cotransporters. Am J Physiol Renal Physiol 280(1):F10–F18

    Article  CAS  Google Scholar 

  5. Wright EM, Loo DD, Hirayama BA (2011) Biology of human sodium glucose transporters. Physiol Rev 91(2):733–794

    Article  CAS  Google Scholar 

  6. Tanaka H, Takano K, Iijima H, Kubo H, Maruyama N, Hashimoto T, Arakawa K, Togo M, Inagaki N, Kaku K (2017) Factors affecting canagliflozin-induced transient urine volume increase in patients with type 2 diabetes mellitus. Adv Ther 34(2):436–451

    Article  CAS  Google Scholar 

  7. Fitchett D, Zinman B, Wanner C, Lachin JM, Hantel S, Salsali A, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE, EMPA-REG OUTCOME(R) trial investigators (2016) Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME(R) trial. Eur Heart J 37(19):1526–1534

    Article  CAS  Google Scholar 

  8. McMurray JJV, Solomon SD, Inzucchi SE, Kober L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Anand IS, Bělohlávek J, Böhm M, Chiang C, Chopra VK, Boer RA, Desai AS, Diez M, Drozdz J, Dukát A, Ge J, Howlett JG, Katova T, Kitakaze M, Ljungman CEA, Merkely B, Nicolau JC, O’Meara E, Petrie MC, Vinh PN, Schou M, Tereshchenko S, Verma S, Held C, DeMets DL, Docherty KF, Jhund PS, Bengtsson O, Sjöstrand M, Langkilde A, DAPA-HF Trial Committees and Investigators (2019) Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med 381(21):1995–2008

    Article  CAS  Google Scholar 

  9. Radholm K, Figtree G, Perkovic V, Solomon SD, Mahaffey KW, de Zeeuw D, Fulcher G, Barrett TD, Shaw W, Desai M, Matthews DR, Neal B (2018) Canagliflozin and heart failure in type 2 diabetes mellitus: results from the CANVAS program. Circulation 138(5):458–468

    Article  CAS  Google Scholar 

  10. Ghosh RK, Ghosh GC, Gupta M, Bandyopadhyay D, Akhtar T, Deedwania P, Lavie CJ, Fonarow GC, Aneja A (2019) Sodium glucose co-transporter 2 inhibitors and heart failure. Am J Cardiol 124(11):1790–1796

    Article  CAS  Google Scholar 

  11. Heerspink HJL, Kosiborod M, Inzucchi SE, Cherney DZI (2018) Renoprotective effects of sodium-glucose cotransporter-2 inhibitors. Kidney Int 94(1):26–39

    Article  CAS  Google Scholar 

  12. JCS Joint Working Group (2013) Guidelines for treatment of acute heart failure (JCS 2011). Circ J 77(8):2157–2201

    Article  Google Scholar 

  13. Lala A, McNulty SE, Mentz RJ, Dunlay SM, Vader JM, AbouEzzeddine OF, DeVore AD, Khazanie P, Redfield MM, Goldsmith SR, Bart BA, Anstrom KJ, Felker GM, Hernandez AF, Stevenson LW (2015) Relief and recurrence of congestion during and after hospitalization for acute heart failure: insights from diuretic optimization strategy evaluation in acute decompensated heart failure (DOSE-AHF) and cardiorenal rescue study in acute decompensated heart failure (CARESS-HF). Circ Heart Fail 8(4):741–748

    Article  Google Scholar 

  14. Fukuoka S, Dohi K, Takeuchi T, Moriwaki K, Ishiyama M, Omori T, Fujimoto N, Ito M (2020) Mechanisms and prediction of short-term natriuretic effect of sodium-glucose cotransporter 2 inhibitor in heart failure patients coexisting type 2 diabetes mellitus. Heart Vessels 35(9):1218–1226

    Article  Google Scholar 

  15. Wang XX, Levi J, Luo Y, Myakala K, Herman-Edelstein M, Qiu L, Wang D, Peng Y, Grenz A, Lucia S, Dobrinskikh E, D’Agati VD, Koepsell H, Kopp JB, Rosenberg AZ, Levi M (2017) SGLT2 Protein expression is increased in human diabetic nephropathy: SGLT2 protein inhibition decreases renal lipid accumulation, inflammation, and the development of nephropathy in diabetic mice. J Biol Chem 292(13):5335–5348

    Article  CAS  Google Scholar 

  16. Cherney DZ, Perkins BA, Soleymanlou N, Maione M, Lai V, Lee A, Fagan NM, Woerle HJ, Johansen OE, Broedl UC, von Eynatten M (2014) Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation 129(5):587–597

    Article  CAS  Google Scholar 

  17. Takiyama Y, Sera T, Nakamura M, Ishizeki K, Saijo Y, Yanagimachi T, Maeda M, Bessho R, Takiyama T, Kitsunai H, Sakagami H, Fujishiro D, Fujita Y, Makino Y, Abiko A, Hoshino M, Uesugi K, Yagi N, Ota T, Haneda M (2018) Impacts of diabetes and an SGLT2 inhibitor on the glomerular number and volume in db/db mice, as estimated by synchrotron radiation micro-CT at SPring-8. EBioMedicine 36:329–346

    Article  Google Scholar 

  18. Kimura T, Sanada J, Shimoda M, Hirukawa H, Fushimi Y, Nishioka M, Kinoshita T, Okauchi S, Obata A, Kohara K, Tatsumi F, Kamei S, Nakanishi S, Mune T, Kaku K, Kaneto H (2018) Switching from low-dose thiazide diuretics to sodium-glucose cotransporter 2 inhibitor improves various metabolic parameters without affecting blood pressure in patients with type 2 diabetes and hypertension. J Diabetes Investig 9(4):875–881

    Article  CAS  Google Scholar 

  19. Wanner C, Inzucchi SE, Lachin JM, Fitchett D, von Eynatten M, Mattheus M, Johansen OE, Woerle HJ, Broedl UC, Zinman B, Investigators EMPA-REGOUTCOME (2016) Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 375(4):323–334

    Article  CAS  Google Scholar 

  20. Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, Edwards R, Agarwal R, Bakris G, Bull S, Cannon CP, Capuano G, Chu P, de Zeeuw D, Greene T, Levin A, Pollock C, Wheeler DC, Yavin Y, Zhang H, Zinman B, Meininger G, Brenner BM, Mahaffey KW, Trial Investigators CREDENCE (2019) Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 380(24):2295–2306

    Article  CAS  Google Scholar 

  21. Mebazaa A, Gayat E, Lassus J, Meas T, Mueller C, Maggioni A, Peacock F, Spinar J, Harjola V, van Kimmenade R, Pathak A, Mueller T, Tavazzi L, Disomma S, Metra M, Pascual-Figal D, Laribi S, Logeart D, Nouira S, Sato N, Parenica J, Deye BNR, Collet C, den Berghe GV, Cohen-Solal A, Januzzi JL Jr, Network GREAT (2013) Association between elevated blood glucose and outcome in acute heart failure: results from an international observational cohort. J Am Coll Cardiol 61(8):820–829

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Cardiovascular Medicine, Kitasato University School of Medicine, 1-15-1 Kitasato, Minami-Ku, Sagamihara, Kanagawa, 252-0374, Japan

    Yuki Ikeda, Shunsuke Ishii, Kenji Maemura, Takumi Oki, Mayu Yazaki, Teppei Fujita, Takeru Nabeta, Emi Maekawa, Toshimi Koitabashi & Junya Ako

Authors
  1. Yuki Ikeda
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Shunsuke Ishii
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kenji Maemura
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Takumi Oki
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Mayu Yazaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Teppei Fujita
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Takeru Nabeta
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Emi Maekawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Toshimi Koitabashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Junya Ako
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yuki Ikeda.

Ethics declarations

Conflict of interest

The authors have no conflicts of interest to disclose.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ikeda, Y., Ishii, S., Maemura, K. et al. Glucose-dependent diuresis in relation to improvements in renal-tubular markers of sodium-glucose cotransporter-2 inhibitors in hospitalized heart failure patients with diabetes. Heart Vessels 36, 978–985 (2021). https://doi.org/10.1007/s00380-020-01768-w

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00380-020-01768-w

Keywords

Search

Navigation